- Home
- AMLX
as 07-26-2024 4:00pm EST
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 160.5M | IPO Year: | 2022 |
| Target Price: | $5.20 | AVG Volume (30 days): | 2.4M |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.07 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.57 - $23.72 | Next Earning Date: | 08-08-2024 |
| Revenue: | $398,001,000 | Revenue Growth: | 324.95% |
| Revenue Growth (this year): | -73.98% | Revenue Growth (next year): | 241.50% |
Stock Insider Trading Activity of Amylyx Pharmaceuticals Inc. (AMLX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Mazzariello Gina | AMLX | Chief Legal Officer | May 15 '24 | Sell | $1.88 | 10,455 | $19,654.35 | 151,477 | SEC Form 4 |
| Quimi Daphne | AMLX | Director | May 14 '24 | Buy | $1.89 | 2,750 | $5,183.75 | 2,750 | SEC Form 4 |
| Quimi Daphne | AMLX | Director | May 14 '24 | Buy | $1.89 | 2,250 | $4,252.28 | 5,000 | SEC Form 4 |
| Mazzariello Gina | AMLX | Chief Legal Officer | Mar 5 '24 | Sell | $18.73 | 1,540 | $28,840.97 | 81,372 | SEC Form 4 |
| Klee Justin B. | AMLX | Co-Chief Executive Officer | Mar 5 '24 | Sell | $18.73 | 4,135 | $77,439.87 | 2,959,308 | SEC Form 4 |
| FRATES JAMES M | AMLX | Chief Financial Officer | Mar 5 '24 | Sell | $18.73 | 1,792 | $33,560.40 | 134,784 | SEC Form 4 |
| Cohen Joshua B | AMLX | Co-Chief Executive Officer | Mar 5 '24 | Sell | $18.73 | 4,135 | $77,439.87 | 3,023,002 | SEC Form 4 |
| Mazzariello Gina | AMLX | Chief Legal Officer | Feb 23 '24 | Sell | $18.76 | 2,838 | $53,230.66 | 46,245 | SEC Form 4 |
| FRATES JAMES M | AMLX | Chief Financial Officer | Jan 9 '24 | Sell | $16.33 | 2,716 | $44,347.12 | 112,035 | SEC Form 4 |
| Cohen Joshua B | AMLX | Co-Chief Executive Officer | Jan 9 '24 | Sell | $16.33 | 5,841 | $95,372.43 | 2,900,470 | SEC Form 4 |
| Klee Justin B. | AMLX | Co-Chief Executive Officer | Jan 9 '24 | Sell | $16.33 | 5,841 | $95,372.43 | 2,836,776 | SEC Form 4 |
| Yeramian Patrick D | AMLX | Chief Medical Officer | Jan 9 '24 | Sell | $16.33 | 2,812 | $45,914.62 | 205,605 | SEC Form 4 |
| Firestone Karen | AMLX | Director | Dec 15 '23 | Buy | $14.97 | 4,000 | $59,880.00 | 5,000 | SEC Form 4 |
Latest Amylyx Pharmaceuticals Inc. News
AMLX Breaking Stock News: Dive into AMLX Ticker-Specific Updates for Smart Investing
MT Newswires
14 days ago
Goldman Sachs Adjusts Price Target on Amylyx Pharmaceuticals to $4 From $3, Maintains Neutral Rating
Clinical Trials Arena
16 days ago
Amylyx to rebuild pipeline with $35m Phase III ready GLP-1RA acquisition
MT Newswires
17 days ago
Amylyx Pharmaceuticals Acquires Avexitide From Eiger BioPharmaceuticals for $35 Million
Business Wire
17 days ago
Amylyx Pharmaceuticals Announces Acquisition of Phase 3-ready GLP-1 Receptor Antagonist (Avexitide) with FDA Breakthrough Therapy Designation
BioPharma Dive
17 days ago
Amylyx, with GLP-1 buy, doubles down on blood sugar drugs
Business Wire
17 days ago
Amylyx Pharmaceuticals to Host Conference Call to Discuss the Acquisition of Avexitide
Pharmaceutical Technology
a month ago
Amylyx ventures into metabolic diseases market with $35.1m deal
Business Wire
2 months ago
Amylyx Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
Compare AMLX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AMLX Amylyx Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.